Black Diamond Therapeutics, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Black Diamond is expanding silevertinib into glioblastoma, adding long-term CNS-driven optionality while NSCLC remains the nearer-term focus.
BDTX's Q1 beat and cash runway into 2028 keep focus on silevertinib's clinical durability, CNS profile and pivotal path.
Black Diamond's May 2026 silevertinib update showed steady NSCLC response rates, CNS activity and dose progress, but durability data remain early.
Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action.
Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
The market is buzzing with gapping stocks on Friday. Let's uncover which stocks are experiencing notable gaps during today's session.
Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational therapy produced a preliminary median progression-free survival of 15.2 months in the study coh
Preliminary mPFS of 15.2 months; mDOR not reachedRobust CNS activity, with 86% CNS ORR; no patients developed de novo brain metastasesORR 60% in patients with a broad spectrum of EGFR-NCMs, including PACCDose dependent
Black Diamond stock rises after its Q1 results reflect lower costs, a cash runway into 2028 and continued progress for lead candidate silevertinib.
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Discover why small-cap indexes lag large caps and how active screening with an enhanced Magic Formula can uncover small-cap value and manage riskâread now.
Black Diamond Therapeutic (NASDAQ:BDTX) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.03) by 433.33 percent. This is a 116.33 percent decrease over earnings of $0.98
CAMBRIDGE, Mass. — CAMBRIDGE, Mass. — Black Diamond Therapeutics, Inc. on Thursday reported a first-quarter loss of $9 million, after reporting a profit in the same period a year earlier. The...
Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst patient dosed in the Phase...
BTIG analyst Robert Burns maintains Black Diamond Therapeutic (NASDAQ:BDTX) with a Buy and raises the price target from $10 to $11.
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
Investors need to pay close attention to BDTX stock based on the movements in the options market lately.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 1.64M | $3.50M | 0.01% | Added+73.1% | 2026-03-31 |
| FidelityFMR | fundamental | 623.8K | $1.33M | 0.00% | Added+15.3% | 2026-03-31 |
| DEShaw | quant | 363.9K | $775.15K | 0.00% | Trimmed-44.5% | 2026-03-31 |
| StateStreet | passive | 213.5K | $454.78K | 0.00% | Unchanged | 2026-03-31 |
| Citadel | multi-strat | 101.0K | $215.10K | 0.00% | Trimmed-48.7% | 2026-03-31 |
| TwoSigma | quant | 43.3K | $92.23K | 0.00% | New | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.20 | — | — |
| 2026-05-07 | -0.21 | -0.16 | +25.23% |
| 2026-03-16 | -0.17 | -0.14 | +19.94% |
| 2025-11-06 | -0.23 | -0.15 | +34.31% |
| 2025-08-07 | -0.23 | -0.19 | +18.57% |
| 2025-05-12 | -0.25 | 0.98 | +484.31% |
| 2025-03-06 | -0.31 | -0.28 | +10.91% |
| 2024-11-05 | -0.36 | -0.28 | +21.50% |
| 2024-08-06 | -0.39 | -0.36 | +6.74% |
| 2024-05-09 | -0.43 | -0.35 | +18.22% |
| 2024-03-12 | -0.46 | -0.34 | +26.09% |
| 2023-11-06 | -0.49 | -0.45 | +8.54% |
| 2023-08-11 | -0.52 | -0.52 | +0.38% |
| 2023-05-09 | -0.61 | -0.57 | +6.56% |
| 2023-03-09 | -0.60 | -0.59 | +2.48% |
| 2022-11-08 | -0.62 | -0.60 | +3.61% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BDTX | -14.62% | -3.48% | -8.64% | +0.91% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -17.58% | +1.16% | -5.20% | -11.78% |